Ref (type)	Population	Outcome, Interventions	Results and statistical analysis	Effect size	Favours
Overall improvement
RCT	90 people with CFS (Australian criteria) In review	Proportion of people reporting improvement on self-reported global improvement scale 6 weeks 24/47 (51%) with moclobemide (450–600 mg/day) 14/43 (33%) with placebo	OR 2.16 95% CI 0.90 to 5.10		Not significant
RCT	90 people with CFS (Australian criteria) In review	Standardised improvement on Karnofsky scale 6 weeks 0.86 with moclobemide (450–600 mg/day) 0.58 with placebo	Mean difference +0.28 95% CI –0.2 to +0.8		Not significant